Abstract
Rheumatoid Arthritis (RA) is an incurable long-term disease that requires continuous safe treatment. Currently, many antiinflammatory agents and steroids are used to manage the diseases and are associated with a variety of side effects. There is a great need for a formulation that addresses the root cause of the disease and can be used for prolonged periods without any side effects. Hence, an attempt was made to develop a formulation of an alternative to steroid formulations that can be used for prolonged periods without/minimal side effects, i.e., teriflunomide topical dosage form. Teriflunomide tablet was approved for multiple sclerosis. It is the primary metabolite of leflunomide which is approved to treat RA. When leflunomide is administered orally converts to teriflunomide to elicit its action as such, leflunomide has no anti-rheumatoid effect. Both leflunomide and teriflunomide have different GIT side effects such as diarrhea, nausea, and hepatotoxicity on oral administration. To avoid these oral side effects of leflunomide and teriflunomide and to improve RA treatment compliance, teriflunomide was formulated as a topical cream. The developed topical cream is designed to be applied at night on the affected joints. It is intended to release the drug during the night, provide higher localized concentrations of the drug in the synovial joint and reduce GI and systemic side effects improving treatment compliance.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
